27 results
8-K
EX-10.1
NRBO
NeuroBo Pharmaceuticals Inc
22 Dec 22
Departure of Directors or Certain Officers
5:08pm
; debt levels; operating profit or net operating profit; workforce diversity; growth of net income or operating income; billings; product development
8-K
EX-10.1
NRBO
NeuroBo Pharmaceuticals Inc
14 Sep 22
Entry into a Material Definitive Agreement
5:11pm
(excluding strikes by the Party’s own workforce or the workforce of any of such Party’s subcontractors within such Party’s reasonable control), or any other
424B3
tw2l9kof300lgnbi0nke
30 Apr 21
Prospectus supplement
5:13pm
424B3
1vpoo0bqtim03vany
1 Feb 21
Prospectus supplement
4:19pm
424B3
517q0 q063j
29 Jan 21
Prospectus supplement
9:20am
424B3
p63ydn1ket3w5p12d
6 Nov 19
Prospectus supplement
9:15am
S-4/A
ds3h3uc2zip54ced
10 Oct 19
Registration of securities issued in business combination transactions (amended)
9:35pm
S-4
roehgxg0wo
3 Sep 19
Registration of securities issued in business combination transactions
12:00am
8-K
EX-99.1
50t49svfifqu
15 Mar 19
Gemphire Therapeutics Reports Fourth Quarter and Fiscal Year 2018 Financial Results
8:05am